CN102652819B - 一种妇炎康分散片及其制备方法 - Google Patents
一种妇炎康分散片及其制备方法 Download PDFInfo
- Publication number
- CN102652819B CN102652819B CN201210057372.9A CN201210057372A CN102652819B CN 102652819 B CN102652819 B CN 102652819B CN 201210057372 A CN201210057372 A CN 201210057372A CN 102652819 B CN102652819 B CN 102652819B
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- vinegar
- rhizoma
- processed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 239000007919 dispersible tablet Substances 0.000 title abstract description 12
- 235000021419 vinegar Nutrition 0.000 claims abstract description 106
- 239000000052 vinegar Substances 0.000 claims abstract description 106
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 241000218176 Corydalis Species 0.000 claims abstract description 27
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000000341 volatile oil Substances 0.000 claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims description 64
- 230000004054 inflammatory process Effects 0.000 claims description 64
- 235000019441 ethanol Nutrition 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 28
- 239000007888 film coating Substances 0.000 claims description 23
- 238000009501 film coating Methods 0.000 claims description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- 210000000582 semen Anatomy 0.000 claims description 22
- 229920001983 poloxamer Polymers 0.000 claims description 21
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 20
- 239000006071 cream Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 17
- 235000019202 steviosides Nutrition 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 12
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000008119 colloidal silica Substances 0.000 claims description 12
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 12
- 229960000502 poloxamer Drugs 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 235000004879 dioscorea Nutrition 0.000 claims description 11
- 241000234273 Dioscorea Species 0.000 claims description 10
- 235000005903 Dioscorea Nutrition 0.000 claims description 10
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 8
- 229940049654 glyceryl behenate Drugs 0.000 claims description 8
- 229940013618 stevioside Drugs 0.000 claims description 8
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 5
- 229920006393 polyether sulfone Polymers 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 210000005056 cell body Anatomy 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 241000600871 Euryale <brittle star> Species 0.000 claims 5
- 244000268590 Euryale ferox Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 12
- 239000006185 dispersion Substances 0.000 abstract description 11
- 238000000605 extraction Methods 0.000 abstract description 9
- 238000003809 water extraction Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- 240000007164 Salvia officinalis Species 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 238000007670 refining Methods 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000301850 Cupressus sempervirens Species 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 240000000233 Melia azedarach Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 206010025482 malaise Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 56
- 239000000243 solution Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 238000001228 spectrum Methods 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000012567 medical material Substances 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 9
- 229920001864 tannin Polymers 0.000 description 9
- 235000018553 tannin Nutrition 0.000 description 9
- 239000001648 tannin Substances 0.000 description 9
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 4
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 4
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 4
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 4
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- -1 destarching Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 229960003371 protocatechualdehyde Drugs 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229920003020 cross-linked polyethylene Polymers 0.000 description 3
- 239000004703 cross-linked polyethylene Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 208000007106 menorrhagia Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010050697 Fallopian tube cyst Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 241000762515 Hydrosalpinx Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010051458 Myometritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000030843 hydrosalpinx Diseases 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210057372.9A CN102652819B (zh) | 2012-03-06 | 2012-03-06 | 一种妇炎康分散片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210057372.9A CN102652819B (zh) | 2012-03-06 | 2012-03-06 | 一种妇炎康分散片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102652819A CN102652819A (zh) | 2012-09-05 |
CN102652819B true CN102652819B (zh) | 2014-05-28 |
Family
ID=46728651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210057372.9A Active CN102652819B (zh) | 2012-03-06 | 2012-03-06 | 一种妇炎康分散片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102652819B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103157062B (zh) * | 2012-11-09 | 2015-03-18 | 深圳市国源药业有限公司 | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 |
CN103412059B (zh) * | 2013-04-17 | 2015-12-09 | 深圳国源国药有限公司 | 一种妇炎康分散片质量控制方法 |
CN103709329B (zh) * | 2013-11-26 | 2016-04-20 | 深圳国源国药有限公司 | 一种妇炎康分散片药用辅料化合物及其制备方法与应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1679650A (zh) * | 2004-04-05 | 2005-10-12 | 魏秀华 | 一种妇炎康制剂 |
CN1303981C (zh) * | 2004-12-22 | 2007-03-14 | 叶耀良 | 妇炎康制剂的制备方法 |
-
2012
- 2012-03-06 CN CN201210057372.9A patent/CN102652819B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102652819A (zh) | 2012-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078473B (zh) | 一种治疗慢性乙型肝炎的中药制剂及其制备方法 | |
CN101972338B (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN103041173A (zh) | 一种治疗皮炎、湿疹的中药外用制剂及其制备方法 | |
CN104784505A (zh) | 一种辅助降血糖的铁皮石斛保健品及其制备方法 | |
CN102652819B (zh) | 一种妇炎康分散片及其制备方法 | |
CN102000164A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN101732668A (zh) | 一种治疗泌尿系统感染的中药组合物的制备方法 | |
CN102846824B (zh) | 一种治疗寒湿血瘀阻络型糖尿病足的中药组合物及其制备方法 | |
CN104435686A (zh) | 一种中药制剂在制备治疗皮肤瘙痒、粟疮药物中的用途 | |
CN103989996B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN102526639B (zh) | 治疗高血脂症的中药组合物及其制备方法 | |
US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
CN103110100A (zh) | 一种朝医保健食品组合物及其制备方法和用途 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN102309705A (zh) | 一种降低血尿酸的药物及其制备方法和用途 | |
CN106492067B (zh) | 一种治疗寻常型银屑病的中药组合物、其制备方法及剂型和应用 | |
CN104605344A (zh) | 一种增强免疫力的保健食品及其制备方法 | |
CN103638336A (zh) | 全天麻片 | |
CN103263581A (zh) | 用于降血糖的双参胶囊 | |
CN107213426A (zh) | 治疗乳腺疾病的中成药及其制备方法 | |
CN105663434A (zh) | 一种治疗变应性皮肤血管炎的中药及制备方法 | |
CN100443093C (zh) | 治疗艾滋病的药物 | |
CN106237206A (zh) | 一种治疗肿瘤的中药制剂及其制备方法 | |
CN106039230A (zh) | 一种治疗乳腺小叶增生的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN GUOYUAN CHINESE MEDICINE CO., LTD. Free format text: FORMER NAME: SHENZHEN GUOYUAN PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 518114, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee after: SHENZHEN GUOYUAN MEDICINES Co.,Ltd. Address before: 518114, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee before: Shenzhen Guoyuan Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171013 Address after: 528449 Guangdong province Zhongshan Nanlang town of Southern China City, modern Chinese medicine Kang Street No. 12 Patentee after: GUANGDONG GUOYUAN GUOYAO PHARMACEUTICAL Co.,Ltd. Address before: 518114, Guangdong District, Shenzhen, Longgang Province on the South Bay Street Li Long community, Li Lang North Road No. 5 workshop 4-5, building 101, 3, B District Patentee before: SHENZHEN GUOYUAN MEDICINES Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 528449 12 Southern China modern Chinese medicine city, Nan Lang Town, Zhongshan, Guangdong. Patentee after: Guoyuan Guoyao (Guangdong) Pharmaceutical Group Co.,Ltd. Address before: 528449 12 Southern China modern Chinese medicine city, Nan Lang Town, Zhongshan, Guangdong. Patentee before: GUANGDONG GUOYUAN GUOYAO PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230224 Address after: 528400 floor 1, building a, No. 12, Kangke street, South China Modern Traditional Chinese medicine city, Nanlang Town, Zhongshan City, Guangdong Province Patentee after: Guangdong Quanrui Pharmaceutical Co.,Ltd. Address before: 528449 12 Southern China modern Chinese medicine city, Nan Lang Town, Zhongshan, Guangdong. Patentee before: Guoyuan Guoyao (Guangdong) Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right |